Abstract
The human prothymosin alpha (PTα) gene encodes a 12.5 kDa highly acidic nuclear protein that is widely expressed in mammalian tissues including the heart and importantly, is detectable also in blood serum. During apoptosis or necrosis, PTα changes its nuclear localization and is able to exert an important cytoprotective effect. Since the role of PTα in the heart has never been evaluated, the aim of the present study was to investigate the effects of PTα on cardiomyocytes during ischemic injury. Our data show that seven after myocardial infarction (MI), PTα expression levels are significantly increased both in blood serum and in cardiac tissue, and notably we observe that PTα translocates from the nuclei to cytoplasm and plasma membrane of cardiomyocytes following MI. Furthermore, in vitro experiments in cardiomyocytes, confirm that after 6 h of simulated ischemia (SI), PTα protein levels are upregulated compared to normoxic cells. Importantly, treatment of cardiomyocytes with a recombinant PTα (rPTα), during SI results in a significant decrease in the apoptotic response and in a robust increase in cell survival. Moreover, these effects are accompanied to a significant preservation of the activated levels of the anti-apoptotic serine-threonine kinase Akt. Consistent with our in vitro observation, rPTα-treated MI mice exhibit a strong reduction in infarct size at 24 h, compared to the MI control group and at the molecular level, PTα treatment induces activation of Akt. The present study provides for the first time the demonstration that PTα offers cardioprotection against ischemic injury by an Akt-dependent mechanism.
Similar content being viewed by others
References
Crow MT, Mani K, Nam YJ, Kitsis RN (2004) The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 95:957–970
Gill C, Mestril R, Samali A (2002) Losing heart: the role of apoptosis in heart disease—a novel therapeutic target? Faseb J 16:135–146
Logue SE, Gustafsson AB, Samali A, Gottlieb RA (2005) Ischemia/reperfusion injury at the intersection with cell death. J Mol Cell Cardiol 38:21–33
Regula KM, Kirshenbaum LA (2005) Apoptosis of ventricular myocytes: a means to an end. J Mol Cell Cardiol 38:3–13
Whelan RS, Mani K, Kitsis RN (2007) Nipping at cardiac remodeling. J Clin Investig 117:2751–2753
Lymperopoulos A, Rengo G, Koch WJ (2007) Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol Med 13:503–511
Kitsis RN, Narula J (2008) Introduction cell death in heart failure. Heart Fail Rev 13:107–109
Mani K, Kitsis RN (2003) Myocyte apoptosis: programming ventricular remodelling. J Am Coll Cardiol 41:761–764
Sutton MG, Sharpe N (2000) Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101:2981–2988
Rengo G, Perrone Filardi P, Femminella GD, Liccardo D, Zincarelli C, de Lucia C, Pagano G, Marsico F, Lymperopoulos A, Leosco D (2012) Targeting β-adrenergic receptor system via G-protein coupled receptor kinase 2 (GRK2): a new paradigm for therapy and prognostic evaluation in heart failure. FROM BENCH TO BEDSIDE. Circ Heart Fail 5:385–391
Rengo G, Lymperopoulos A, Leosco D, Koch WJ (2011) GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 50:785–792
Evsta¢eva GA, Belov GA, Kalkum M, Chichkova NV, Bogdanov AA, Agol VI, Vartapetian AB (2000) Prothymosin K fragmentation in apoptosis. FEBS Lett 467:150–154
Ueda H, Fujita R, Yoshida A, Matsunaga H, Ueda M (2007) Identification of prothymosin-alpha 1, the necrosis–apoptosis switch molecule in cortical neuronal cultures. J Cell Biol 176(6):853–862
Letsas KP, Frangou-Lazaridis M (2006) Surfing on prothymosin alpha proliferation and anti-apoptotic properties. Neoplasma 53(2):92–96
Barbini L, Gonzalez R, Dominguez F, Vega F (2006) Apoptotic and proliferating hepatocytes differ in prothymosin alpha expression and cell localization. Mol Cell Biochem 291(1–2):83–91
Hannappel E, Huff T (2003) The thymosins, prothymosin alpha, parathymosin, and alpha-thymosins: structure and function. Vitam Horm 66:257–295
Mosoian A, Teixeira A, Burns CS, Sander LE, Gusella GL, He C, Blander JM, Klotman P, Klotman ME (2010) Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc Natl Acad Sci USA 107(22):10178–10183
Salgado FJ, Piñeiro A, Canda-Sánchez A, Lojo J, Nogueira M (2005) Prothymosin alpha-receptor associates with lipid rafts in PHA-stimulated lymphocytes. Mol Membr Biol 22(3):163–176
Franco FJ, Diaz C, Barcia M, Arias P, Gomez-Marquez J, Soriano F, Mendez E, Freire M (1989) Synthesis and apparent secretion of prothymosin alpha by different subpopulations of calf and rat thymocytes. Immunology 67(2):263–268
Panneerselvam C, Haritos AA, Caldarella J, Horecker BL (1987) Prothymosin alpha in human blood. Proc Natl Acad Sci USA 84:4465–4469
Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW 2nd, Koch WJ (2010) Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem 285:16378–16386
Rengo G, Zincarelli C, Femminella GD, Liccardo D, Pagano G, de Lucia C, Altobelli GG, Cimini V, Ruggiero D, Perrone-Filardi P, Gao E, Ferrara N, Lymperopoulos A, Koch WJ, Leosco D (2012) Myocardial β2-adrenergic receptor gene delivery promotes coordinated cardiac adaptive remodeling and angiogenesis in heart failure. Br J Pharmacol 166:2348–2361
Tohgo A, Pierce KL, Choy EW, Lefkowitz RJ, Luttrell LM (2002) beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem 277:9429–9436
Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ, Gold J, Gumpert A, Chen M, otis NJ, Dorn GW II, Trimarco B, Iaccarino G, Koch WJ (2011) GRK2 activity impairs cardiac glucose uptake and promotes insulin resistance following myocardial ischemia. Circulation 123:1953–1962
Esposito G, Perrino C, Cannavo A, Schiattarella GG, Borgia F, Sannino A, Pironti G, Gargiulo G, Di Serafino L, Franzone A, Scudiero L, Grieco P, Indolfi C, Chiariello M (2011) EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Res Cardiol 106:577–589
Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ (2009) An adrenal β-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci USA 106:5825–5830
Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19:6341–6350
Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ (2009) Myocardial AAV6-βARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119:89–98
Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ (2011) Adrenal β-arrestin-1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol 57:356–365
Cook CA, Matsui C, Li L, Rosenzweig A (2002) Transcriptional effects of chronic Akt activation in the heart. J Biol Chem 277:22528–22533
Saraste A (1999) Morphologic criteria and detection of apoptosis. Herz 24(3):189–195
Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516
Guaiquil VH, Golde DW, Beckles DL, Mascareno EJ, Siddiqui MA (2004) Vitamin C inhibits hypoxia-induced damage and apoptotic signaling pathways in cardiomyocytes and ischemic hearts. Free Radic Biol Med 37(9):1419–1429
Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K (2000) Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660–667
Matsui T, Nagoshi T, Rosenzweig A (2003) Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2(3):220–223
Leosco D, Rengo G, Iaccarino G, Golino L, Marchese M, Fortunato F, Zincarelli C, Sansari E, Ciccarelli M, Galasso G, Altobelli GG, Conti V, Matrone G, Cimini V, Ferrara N, Filippelli A, Koch WJ, Rengo F (2008) Exercise promotes angiogenesis and improves β-adrenergic receptor signaling in the post-ischemic failing rat heart. Cardiovasc Res 78:385–394
Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P (1996) Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Investig 74:86–107
Acknowledgments
This work has been supported in part by the Grant PRIN 2007 (No. 2007WS3JL3) from the Ministero dell’Università e della Ricerca Scientifica.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Cannavo, A., Rengo, G., Liccardo, D. et al. Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation. Apoptosis 18, 1252–1261 (2013). https://doi.org/10.1007/s10495-013-0876-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10495-013-0876-9